Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis

Abstract

The present study shows that GLUT-1 served as a marker indicating that tumors with deep invasion tended to result in a worse prognosis in patients due to either lymph node metastasis, a recurrence of the primary lesion or distant metastasis.

GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma

“…Among the 10 PDSCC cases, only 1 (10%) showed mild staining and 9 (90%) showed intense staining. These findings accord with those of Reisser and Ohba in OSCC (8,13).…”

“…It has been suggested that altered GLUT-1 expression is the initial change evident in not only OSCC, but also nonsmall cell lung carcinoma and various other carcinomas including those of the esophagus, colon, colorectum, stomach, breast, uterine cervix and pancreas, being positively correlated with aggressive tumor behavior and poor prognosis (8). Furthermore, enhanced GLUT-1 expression has been noted in premalignant lesions (9).…”

“…Although the metabolic consequences of increased glucose transport associated with enhanced GLUT-1 expression are still unclear, its clinical implications in numerous malignancies have been suggested (8). Although GLUT-1 overexpression is consistently evident in patients with head and neck squamous cell carcinoma, its prognostic value has not been analyzed systematically, particularly in the context of OED and OSCC (7).…”

Expression and clinical significance of glucose transporter-1 in pancreatic cancer

“…A number of studies have demonstrated a close association between GLUT-1 expression and malignant mesothelium, which is relevant for the clinical behavior of the tumor (14,21,22). The results of the present study indicated that GLUT-1 was overexpressed in pancreatic cancer and was associated with clinicopathological characteristics, including tumor size, clinical stage and lymph node metastasis.…”

“…Glucose transporter-1 (GLUT-1) is a member of the GLUT family, which is expressed in erythrocytes, endothelial cells, placenta and blood-tissue barriers, including the blood-brain and blood-nerve barriers (10,11). Recent studies have demonstrated that GLUT-1 is often upregulated in various malignant tumors, including colorectal cancer (12), esophageal cancer (13), oral squamous cell carcinoma (14), renal cell carcinoma (15) breast cancer and lung cancer (16). It is also considered to be the predominantly elevated glucose transporter under ischemic and hypoxic conditions, whereby cells require glycolysis as an energy source.…”